Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Pfizer (PFE)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
$30.79+2.63%
Close 2026-11-04 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
2.90 → 2.92 EPS · FY ending Dec 31, 2027 · 13 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 14 to 13; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for PFE yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
5 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Adjusted diluted EPS between $2.80 and $3.00 in 2026 | Adjusted EPS is expected between $2.80 and $3.00. | Under Pressure | Adjusted EPS falls below $2.80 or above $3.00 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a large pharmaceutical company with a multi-year thesis based on operational delivery, cost savings, and new medicines from its research pipeline. The thesis is intact, though its signal has eased from favorable to mildly favorable and recent financial performance is neutral.
The valuation evidence describes Pfizer as cheap versus peers, with expectations near the model’s baseline and low signs of fragility. That leaves some room for the business to meet expectations, but does not remove the need to deliver on guidance and cost savings.
Near term, management has reaffirmed full-year 2026 guidance and raised its revenue outlook, while quarterly revenue increased from the first quarter to the second. Cost-savings delivery is mixed, and the plan for about 20 pivotal study starts in 2026 supports the longer-term pipeline; recent results and execution still need to sustain the thesis.
A guidance cut would be a meaningful negative, while continued delivery against the reaffirmed outlook would support the near-term case. Over the multi-year view, the key swing factors are achieving the cost-savings goals and turning pipeline progress into medicines, alongside broader Healthcare-sector results and economic conditions.
Over the next one to three years, Pfizer’s thesis rests on steady execution, savings, and pipeline progress; the evidence is supportive but not conclusive. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Pfizer's published investment case. The stated target is Sustain dividend growth and share repurchase flexibility. |
| Intact |
| Dividend payments decline materially or share repurchase authorization withdrawn |
Dividends paid: $2.445B FY2025-Q4; GAAP. Published target: Sustain dividend growth and share repurchase flexibility. Target period is not explicitly aligned with this observation. Date unavailable2,445,000,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 6 of 8 supplied quarters. Management reported: “Our capital allocation framework is designed to enhance long-term shareholder value, and is based on three core pillars: (i) reinvesting in the business, including maintaining the flexibility to deploy capital towards potential value- - 3 - creating business development transactions, (ii) maintaining and, over the long term, growing our dividend, and (iii) in the future, the potential to resume the return of capital to shareholders through value-enhancing share repurchases after de-levering our balance sheet.” “Current financial guidance does not anticipate any share repurchases in 2026.” Delivery assessment Nov 4, 2026 |
Achieve $5.7 billion net cost savings by end of 2027 | The company targets $5.7 billion in cost savings by 2027. | Intact | Net cost savings fall short of $5.7 billion by end of 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 6 of 8 supplied quarters. Management reported: “Across the studies, both the 50 and 100 milligram doses of Litfulo delivered significant, clinically meaningful improvements over placebo on co-primary endpoints for the facial and total body Vitiligo Area Scoring Index, or VASI.” “The safety profile of Litfulo in NSV was consistent with the established safety profile in alopecia areata.” Delivery assessment Nov 4, 2026 |
Manage risks from drug pricing policies in key markets | A supporting condition in Pfizer's published investment case. The stated target is No material revenue impact from pricing policies. | Intact | Material revenue declines due to drug pricing policy changes | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Full-year 2026 revenue in range $59.5 to $62.5 billion | Pfizer keeps its full-year 2026 revenue guidance of up to $62.5 billion. | Under Pressure | Full-year revenue falls below $59.5 billion or above $62.5 billion | Revenue: $16.583B FY2026-Q3; GAAP. Published target: >= $59.5 billion and <= $62.5 billion. Annual target cannot be compared with a quarterly or TTM observation. Nov 3, 202616,583,000,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$2.83 → $2.92 · observed estimates
$59.20B → $60.41B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $2.83 | $59,201,610,900 | 24 / 23 |
| 2026-07-25 | $2.83 | $59,373,166,570 | 24 / 24 |
| 2026-07-26 | $2.84 | $59,300,515,971 | 13 / 17 |
| 2026-07-27 | $2.84 | $59,300,515,971 | 13 / 17 |
| 2026-07-28 | $2.83 | $59,373,166,570 | 24 / 24 |
| 2026-07-29 | $2.83 | $59,366,541,570 | 24 / 24 |
| 2026-07-30 | $2.83 | $59,366,541,570 | 24 / 24 |
| 2026-07-31 | $2.84 | $59,293,602,928 | 13 / 18 |
| 2026-08-01 | $2.84 | $59,293,602,928 | 13 / 18 |
| 2026-08-02 | $2.83 | $59,366,541,570 | 23 / 24 |
| 2026-08-03 | $2.84 | $59,293,602,928 | 13 / 18 |
| 2026-08-04 | $2.84 | $59,293,602,928 | 13 / 18 |
| 2026-08-05 | $2.84 | $59,293,602,928 | 13 / 18 |
| 2026-08-06 | $2.83 | $59,366,541,570 | 23 / 24 |
| 2026-08-07 | $2.87 | $59,491,238,038 | 13 / 17 |
| 2026-08-08 | $2.88 | $59,760,329,810 | 23 / 23 |
| 2026-08-09 | $2.87 | $59,491,238,038 | 13 / 17 |
| 2026-08-10 | $2.87 | $59,491,238,038 | 13 / 17 |
| 2026-08-12 | $2.87 | $59,491,238,038 | 13 / 17 |
| 2026-08-13 | $2.89 | $59,852,187,580 | 25 / 25 |
| 2026-08-14 | $2.87 | $59,491,238,038 | 13 / 17 |
| 2026-08-15 | $2.87 | $59,491,238,038 | 14 / 18 |
| 2026-08-16 | $2.87 | $59,491,238,038 | 14 / 18 |
| 2026-08-17 | $2.87 | $59,491,238,038 | 14 / 18 |
| 2026-08-18 | $2.87 | $59,491,238,038 | 14 / 18 |
| 2026-08-19 | $2.87 | $59,491,238,038 | 14 / 18 |
| 2026-08-20 | $2.89 | $59,719,626,044 | 14 / 18 |
| 2026-08-21 | $2.89 | $59,719,626,044 | 14 / 18 |
| 2026-08-22 | $2.89 | $59,719,626,044 | 14 / 18 |
| 2026-08-23 | $2.89 | $59,719,626,044 | 14 / 18 |
| 2026-08-24 | $2.89 | $59,719,626,044 | 14 / 18 |
| 2026-08-25 | $2.89 | $59,719,626,044 | 14 / 18 |
| 2026-08-26 | $2.89 | $59,719,626,044 | 14 / 18 |
| 2026-08-27 | $2.89 | $59,719,626,044 | 14 / 18 |
| 2026-08-28 | $2.89 | $59,719,626,044 | 14 / 18 |
| 2026-08-29 | $2.89 | $59,719,626,044 | 14 / 18 |
| 2026-08-30 | $2.89 | $59,719,626,044 | 14 / 18 |
| 2026-08-31 | $2.89 | $59,719,626,044 | 14 / 18 |
| 2026-09-01 | $2.89 | $59,719,626,044 | 14 / 18 |
| 2026-09-02 | $2.89 | $59,719,626,044 | 14 / 18 |
| 2026-09-03 | $2.89 | $59,719,641,452 | 14 / 18 |
| 2026-09-04 | $2.89 | $59,719,641,452 | 14 / 18 |
| 2026-09-05 | $2.89 | $59,719,641,452 | 14 / 18 |
| 2026-09-06 | $2.89 | $59,719,641,452 | 14 / 18 |
| 2026-09-07 | $2.89 | $59,719,641,452 | 14 / 18 |
| 2026-09-08 | $2.89 | $59,719,641,452 | 14 / 18 |
| 2026-09-09 | $2.89 | $59,719,642,722 | 14 / 18 |
| 2026-09-10 | $2.90 | $59,762,908,296 | 14 / 18 |
| 2026-09-11 | $2.90 | $59,762,908,296 | 14 / 18 |
| 2026-09-12 | $2.90 | $59,762,908,296 | 14 / 18 |
| 2026-09-13 | $2.90 | $59,762,908,296 | 14 / 18 |
| 2026-09-14 | $2.90 | $59,762,908,296 | 14 / 18 |
| 2026-09-15 | $2.90 | $59,762,908,296 | 14 / 18 |
| 2026-09-16 | $2.90 | $59,762,908,296 | 14 / 18 |
| 2026-09-17 | $2.90 | $59,762,908,296 | 14 / 18 |
| 2026-09-18 | $2.90 | $59,762,908,296 | 14 / 18 |
| 2026-09-19 | $2.90 | $59,762,908,296 | 14 / 18 |
| 2026-09-20 | $2.90 | $59,762,921,340 | 14 / 18 |
| 2026-09-21 | $2.90 | $59,762,921,340 | 14 / 18 |
| 2026-09-22 | $2.90 | $59,762,921,340 | 14 / 18 |
| 2026-09-23 | $2.90 | $59,762,908,296 | 14 / 18 |
| 2026-09-24 | $2.90 | $59,762,908,296 | 14 / 18 |
| 2026-09-25 | $2.90 | $59,762,908,296 | 14 / 18 |
| 2026-09-26 | $2.90 | $59,762,920,927 | 14 / 18 |
| 2026-09-27 | $2.90 | $59,762,920,927 | 14 / 18 |
| 2026-09-28 | $2.90 | $59,762,920,927 | 14 / 18 |
| 2026-09-29 | $2.90 | $59,762,920,927 | 14 / 18 |
| 2026-09-30 | $2.90 | $59,762,920,927 | 14 / 18 |
| 2026-10-01 | $2.90 | $59,762,920,927 | 14 / 18 |
| 2026-10-02 | $2.90 | $59,762,919,657 | 14 / 18 |
| 2026-10-03 | $2.90 | $59,762,920,117 | 14 / 18 |
| 2026-10-04 | $2.90 | $59,762,920,117 | 14 / 18 |
| 2026-10-05 | $2.90 | $59,762,920,117 | 14 / 18 |
| 2026-10-06 | $2.90 | $59,762,920,117 | 14 / 18 |
| 2026-10-07 | $2.90 | $59,790,528,813 | 14 / 18 |
| 2026-10-08 | $2.90 | $59,800,054,991 | 14 / 18 |
| 2026-10-09 | $2.90 | $59,824,337,139 | 14 / 18 |
| 2026-10-10 | $2.90 | $59,824,337,139 | 14 / 18 |
| 2026-10-11 | $2.90 | $59,822,925,728 | 14 / 18 |
| 2026-10-12 | $2.90 | $59,822,925,728 | 14 / 18 |
| 2026-10-13 | $2.90 | $59,799,382,926 | 14 / 18 |
| 2026-10-14 | $2.90 | $59,789,252,492 | 13 / 17 |
| 2026-10-15 | $2.90 | $59,789,252,492 | 13 / 17 |
| 2026-10-16 | $2.90 | $59,789,252,492 | 13 / 17 |
| 2026-10-17 | $2.90 | $59,789,252,492 | 13 / 17 |
| 2026-10-18 | $2.90 | $59,789,202,683 | 13 / 17 |
| 2026-10-19 | $2.90 | $59,789,202,683 | 13 / 17 |
| 2026-10-20 | $2.90 | $59,789,222,814 | 13 / 17 |
| 2026-10-21 | $2.90 | $59,789,222,813 | 13 / 17 |
| 2026-10-22 | $2.89 | $59,805,874,987 | 13 / 17 |
| 2026-10-23 | $2.89 | $59,822,449,798 | 13 / 17 |
| 2026-10-24 | $2.89 | $59,822,449,798 | 13 / 17 |
| 2026-10-25 | $2.89 | $59,822,449,798 | 13 / 17 |
| 2026-10-26 | $2.89 | $59,822,449,798 | 13 / 17 |
| 2026-10-27 | $2.89 | $59,822,449,798 | 13 / 17 |
| 2026-10-28 | $2.89 | $59,822,425,320 | 13 / 17 |
| 2026-10-29 | $2.90 | $59,836,338,364 | 13 / 17 |
| 2026-10-30 | $2.90 | $59,836,338,364 | 13 / 17 |
| 2026-10-31 | $2.90 | $59,836,338,364 | 13 / 17 |
| 2026-11-01 | $2.90 | $59,836,338,364 | 13 / 17 |
| 2026-11-02 | $2.90 | $59,836,338,364 | 13 / 17 |
| 2026-11-03 | $2.90 | $59,836,338,364 | 13 / 17 |
| 2026-11-04 | $2.92 | $60,406,441,897 | 13 / 17 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 9 Buy / Strong Buy · 17 Hold · 2 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 5 recorded
0 raises · 0 cuts · 0 unchanged · 3 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings5 of 5 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.